Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof|
|Abstract:||This disclosure describes symmetrical 1,4-bis-(substituted-amino)-5,8-hydroxyanthraquinones useful as chelating agents and for inducing regression and/or palliation of cancer diseases in mammals.|
|Inventor(s):||Murdock; Keith C. (Pearl River, NY), Durr; Frederick E. (Ridgewood, NJ)|
|Assignee:||American Cyanamid Company (Stamford, CT)|
|Filing Date:||Apr 09, 1984|
|Claims:||1. A compound selected from the group consisting of those of the formula: ##STR11## wherein Q is a divalent moiety selected from the group consisting of those of the formulae: ##STR12## wherein n is an interger from 2 to 4, inclusive; R.sub.1 and R.sub.2 are each individually selected from the group consisting of hydrogen, alkyl having form 1 to 4 carbon atoms, monohydroxyalkyl having from 2 to 4 carbon atoms and wherein the carbon atom alpha to the nitrogen atom may not bear an hydroxy group and moieties of the formulae: ##STR13## wherein n is an integer from 2 to 4, inclusive, R is alkyl having from 1 to 4 carbon atoms, and R.sub.3 and R.sub.4 taken together with their associated N(itrogen) are morpholino, thiomorpholino, piperazino, 4-methyl-1-piperazino or a moiety of the formula: ##STR14## wherein m is an integer from 2 to 6, inclusive; with the first proviso that the ratio of the total number of carbon atoms to the sum of the total number of oxygen atoms plus the total number of nitrogen atoms in the side-chains at the 1-position and the 4-position may not exceed four and with the second proviso that when either of R.sub.1 or R.sub.2 is monohydroxyalkyl then the other may not be hydrogen, alkyl or monohydroxyalkyl and with the third proviso that R.sub.1 and R.sub.2 may not both be hydrogen or alkyl; the leuco bases and tautomers thereof and the pharmacologically acceptable acid-addition salts thereof. |
2. A compound selected from the group consisting of those of the formula: ##STR15## wherein each n is an integer from 2 to 4, inclusive, and R.sub.3 and R.sub.4 taken together with their associated N(itrogen) are morpholino, thiomorpholino, piperazino, 4-methylpiperazino or a moiety of the formula: ##STR16## wherein m is an integer from 2 to 6, inclusive; the leuco bases and tautomers thereof and the pharmacologically acceptable acid-addition salts thereof.
3. The compound according to claim 2; 1,4-bis-[2-(2-morpholinoethylamino)ethylamino]-5,8-dihydroxyanthraquinone.
4. The compound according to claim 1; 1,4-bis[2-(2-methoxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.